Notably, diminished intestinal AhR expression levels have been reported in patients with IBD compared to healthy volunteers [13], and synthetic AhR ligands have been shown to inhibit inflammation through induction of IL-22 mRNA and protein in T cells from patients with IBD in vitro [14]. This evidence concerns the gene IL22 and inflammatory bowel disease.